Lu Han

28 Fuxing Road
Beijing, 100853, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 antibody) for locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ib/II randomized study.

First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 antibody) for locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ib/II randomized study.

Journal: Signal transduction and targeted therapy

Published: April 26, 2025

Comparative outcomes of first-line PD-1/PD-L1 inhibitors plus chemotherapy for advanced squamous non-small cell lung cancer: a systematic review and network meta-analysis of randomized clinical trials.

Comparative outcomes of first-line PD-1/PD-L1 inhibitors plus chemotherapy for advanced squamous non-small cell lung cancer: a systematic review and network meta-analysis of randomized clinical trials.

Journal: Translational lung cancer research

Published: January 22, 2025

miR-196b strictly regulates and reliably predicts the response to cetuximab in colorectal cancer.

miR-196b strictly regulates and reliably predicts the response to cetuximab in colorectal cancer.

Journal: Cellular & molecular biology letters

Published: January 08, 2025

How do drunk-driving events escalate into drunk-driving crashes? An empirical analysis of Beijing from a spatiotemporal perspective.

How do drunk-driving events escalate into drunk-driving crashes? An empirical analysis of Beijing from a spatiotemporal perspective.

Journal: International journal of injury control and safety promotion

Published: January 27, 2024

High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospective study.

High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospective study.

Journal: Journal of translational medicine

Published: November 26, 2023

Hyperprogressive disease during PD-1 blockade in patients with advanced pancreatic cancer.

Hyperprogressive disease during PD-1 blockade in patients with advanced pancreatic cancer.

Journal: Human vaccines & immunotherapeutics

Published: September 07, 2023

MetaCAE: Causal autoencoder with meta-knowledge transfer for brain effective connectivity estimation.

MetaCAE: Causal autoencoder with meta-knowledge transfer for brain effective connectivity estimation.

Journal: Computers in biology and medicine

Published: August 09, 2023

Pioneer factor Foxa2 mediates chromatin conformation changes in ligand-dependent activation of nuclear receptor FXR.

Pioneer factor Foxa2 mediates chromatin conformation changes in ligand-dependent activation of nuclear receptor FXR.

Journal: bioRxiv : the preprint server for biology

Published: March 22, 2023

Co-assembled nanocomplexes of peptide neoantigen Adpgk and Toll-like receptor 9 agonist CpG ODN for efficient colorectal cancer immunotherapy.

Co-assembled nanocomplexes of peptide neoantigen Adpgk and Toll-like receptor 9 agonist CpG ODN for efficient colorectal cancer immunotherapy.

Journal: International journal of pharmaceutics

Published: June 24, 2021

Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study.

Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study.

Journal: Cancer immunology, immunotherapy : CII

Published: June 24, 2021

The Ratio of IP10 to IL-8 in Plasma Reflects and Predicts the Response of Patients With Lung Cancer to Anti-PD-1 Immunotherapy Combined With Chemotherapy.

The Ratio of IP10 to IL-8 in Plasma Reflects and Predicts the Response of Patients With Lung Cancer to Anti-PD-1 Immunotherapy Combined With Chemotherapy.

Journal: Frontiers in immunology

Published: February 07, 2021

MicroRNA-128 contributes to the progression of gastric carcinoma through GAREM-mediated MAPK signaling activation.

MicroRNA-128 contributes to the progression of gastric carcinoma through GAREM-mediated MAPK signaling activation.

Journal: Biochemical and biophysical research communications

Published: August 18, 2018

Showing 1-12 of 16

Last Updated: 09/26/2026